作者
Troy C Lund, Kwang Woo Ahn, Heather R Tecca, Megan V Hilgers, Hisham Abdel-Azim, Allistair Abraham, Miguel Angel Diaz, Sherif M Badawy, Larisa Broglie, Valerie Brown, Christopher C Dvorak, Marta Gonzalez-Vicent, Hasan Hashem, Robert J Hayashi, David A Jacobsohn, Michael W Kent, Chi-kong Li, Steven P Margossian, Paul L Martin, Parinda Mehta, Kasiani Myers, Richard Olsson, Kristin Page, Michael A Pulsipher, Peter J Shaw, Angela R Smith, Brandon M Triplett, Michael R Verneris, Mary Eapen
发表日期
2019/2/1
期刊
Biology of Blood and Marrow Transplantation
卷号
25
期号
2
页码范围
301-306
出版商
Elsevier
简介
Children with acute leukemia who relapse after hematopoietic cell transplantation (HCT) have few therapeutic options. We studied 251 children and young adults with acute myelogenous or lymphoblastic leukemia who underwent a second HCT for relapse after their first HCT. The median age at second HCT was 11 years, and the median interval between first and second HCT was 17 months. Most of the patients (n = 187; 75%) were in remission, received a myeloablative conditioning regimen (n = 157; 63%), and underwent unrelated donor HCT (n = 230; 92%). The 2-year probability of leukemia-free survival (LFS) was 33% after transplantation in patients in remission, compared with 19% after transplantation in patients not in remission (P = .02). The corresponding 8-year probabilities were 24% and 10% (P = .003). A higher rate of relapse contributed to the difference in LFS. The 2-year probability of …
学术搜索中的文章
TC Lund, KW Ahn, HR Tecca, MV Hilgers… - Biology of Blood and Marrow Transplantation, 2019